HCPCS Level II code J0587 denotes a 100-unit vial of rimabotulinumtoxinb for injection, an FDA-approved botulinum toxin product used in therapeutic settings. Nationally, accurate coding for injectable biologics such as rimabotulinumtoxinb matters for clinical documentation, claims processing, and consistent payment for complex outpatient treatments. This code identifies the specific product and unit quantity, supporting precise billing across care settings where injections are delivered.

Key payers analyzed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on how the code is used in practice, typical sites of service, and the payer landscape relevant to this injectable biologic. The publication summarizes available benchmarks and policy considerations affecting coverage and billing for biologic injections, clarifies common clinical contexts in which rimabotulinumtoxinb is administered, and highlights areas where coding accuracy affects reimbursement and utilization reporting.

The document is intended for billing professionals, practice managers, and policy analysts seeking a national overview of HCPCS Level II code J0587, its clinical role, and the payer environment. Data not provided in the source input are noted where applicable.